Home | Welcome to Contract Pharma   
Last Updated Thursday, August 28 2014
Print RSS Feed

Evotec Earns Boehringer Research Milestone



Published September 30, 2013
Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim triggering a €2.0 million payment to Evotec. The milestone was for the transition of an oncology molecule into Phase I clinical trials.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, "This is a very important 19th milestone for Evotec in our collaboration with Boehringer Ingelheim, as it represents the first oncology compound to progress into Phase I studies. The collaboration continues to drive value for both companies."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On